Ocata Therapeutics Inc fka OCAT

[davpar]

Significant highlights from CC (IMO)

1) First IRB expected within two weeks
2) Possible European trials to coincide with North American trials
3) Too early for partnership discussions
4) First Data expected 12 weeks after trial commencement. Initial data will possibly show not much improvement, but will show cell attachement
5) There will be six patients between the two trials with trials expected to last 12 months
6) We're actively seeking a partner for the Myoblast trials
7) Research is being done to submit an IND for MMD (Myopic Macular Degeneration)
8) Also working on Corneal Diseases
9) Research also being done for Hemangioblast IND
10) We have retained the company Spencer Stuart for our CEO hunt